Attention deficit/hyperactivity disorder MedDRA version: 12.1 Level: LLT Classification code 10003736 Term: Attention deficit/hyperactivity disorder
Conditions
Interventions
Trade Name: Superba(TM) Krill Oil
Pharmaceutical Form: Capsule, soft
Trade Name: 18/12 Fish Oil
Pharmaceutical Form: Capsule, soft
Sponsors
Aker BioMarine Antarctic AS
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: All participants are male ADHD patients of the combined type and are of age 7-11 years. Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Known allergy to crustacean or fish
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate changes in the brain metabolism of juvenile ADHD patients after thirteen weeks of daily doses of 4 g Superba krill oil or 4 g omega-3 enriched fish oil;Secondary Objective: To evaluate if there are changes in the brain metabolism of those who receive Superba krill oil which can be related to a decrease in ADHD symptoms as measured by EEG and/or a clinical assessment. To evaluate if there are changes in the brain metabolism of those who receive Superba krill oil which can be related to a larger decrease in ADHD symptoms as measured by EEG and/or a clinical assessment when compared to those who take in the fish oil.;Primary end point(s): EEG measurements from 40 ADHD patients before and after 13 weeks of treatment with food supplements rich of omega-3 fatty acids. | — |
Countries
Iceland
Outcome results
None listed